MAPT and Alzheimer disease: Another prospective research with different T biomarkers from those of our study consistently indicated that the soluble tau as reflected by elevated plasma p-tau217 and the insoluble tau aggregates as reflected by elevated tau PET (18F-RO948 and 18F-flortaucipir) signals, are optimal predictors for longitudinal tau accumulation in the brains of patients with AD at preclinical and prodromal phases, respectively [18].